249 related articles for article (PubMed ID: 22532636)
41. Clinical significance of high levels of soluble tumour necrosis factor-α receptor-2 produced by alternative splicing in rheumatoid arthritis: a longitudinal prospective cohort study.
Cañete JD; Albaladejo C; Hernández MV; Laínez B; Pinto JA; Ramírez J; López-Armada MJ; Rodríguez-Cros JR; Engel P; Blanco FJ; Sanmartí R
Rheumatology (Oxford); 2011 Apr; 50(4):721-8. PubMed ID: 21134963
[TBL] [Abstract][Full Text] [Related]
42. Comparison of radiographic scoring methods in a cohort of RA patients treated with anti-TNF therapy.
Barnabe C; Hazlewood G; Barr S; Martin L
Rheumatology (Oxford); 2012 May; 51(5):878-81. PubMed ID: 22223704
[TBL] [Abstract][Full Text] [Related]
43. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
[TBL] [Abstract][Full Text] [Related]
44. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
[TBL] [Abstract][Full Text] [Related]
45. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Finckh A; Simard JF; Gabay C; Guerne PA;
Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
[TBL] [Abstract][Full Text] [Related]
46. Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil.
Acurcio FA; Machado MA; Moura CS; Ferre F; Guerra AA; Andrade EI; Cherchiglia ML; Rahme E
Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1489-96. PubMed ID: 26814681
[TBL] [Abstract][Full Text] [Related]
47. Radiological progression in early rheumatoid arthritis after DMARDS: a one-year follow-up study in a clinical setting.
Sanmarti R; Gomez A; Ercilla G; Gratacos J; Larrosa M; Suris X; Vinas O; Salvador G; Munoz-Gomez J; Canete JD
Rheumatology (Oxford); 2003 Sep; 42(9):1044-9. PubMed ID: 12730518
[TBL] [Abstract][Full Text] [Related]
48. A dose of only 5 mg prednisolone daily retards radiographic progression in early rheumatoid arthritis - the Low-Dose Prednisolone Trial.
Wassenberg S; Rau R; Zeidler H;
Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S68-72. PubMed ID: 22018187
[TBL] [Abstract][Full Text] [Related]
49. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.
Eder L; Thavaneswaran A; Chandran V; Gladman DD
Ann Rheum Dis; 2014 Jun; 73(6):1007-11. PubMed ID: 23619157
[TBL] [Abstract][Full Text] [Related]
50. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
[TBL] [Abstract][Full Text] [Related]
51. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J).
Takeuchi T; Yamanaka H; Inoue E; Nagasawa H; Nawata M; Ikari K; Saito K; Sekiguchi N; Sato E; Kameda H; Iwata S; Mochizuki T; Amano K; Tanaka Y
Mod Rheumatol; 2008; 18(5):447-54. PubMed ID: 18493716
[TBL] [Abstract][Full Text] [Related]
52. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.
Naredo E; Möller I; Cruz A; Carmona L; Garrido J
Arthritis Rheum; 2008 Aug; 58(8):2248-56. PubMed ID: 18668537
[TBL] [Abstract][Full Text] [Related]
53. Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment.
Pavelka K; Gatterová J; Tegzová D; Jarosová K; Tomasová Studýnková J; Svobodník A; Svihálek J; Dusek L; Vencovský J
Clin Exp Rheumatol; 2007; 25(4):540-5. PubMed ID: 17888209
[TBL] [Abstract][Full Text] [Related]
54. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
55. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
56. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
57. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group.
Halpern MT; Cifaldi MA; Kvien TK
Ann Rheum Dis; 2009 Jun; 68(6):930-7. PubMed ID: 18829616
[TBL] [Abstract][Full Text] [Related]
58. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
59. Tumour necrosis factor-α inhibitors are glucocorticoid-sparing in rheumatoid arthritis.
Nilsson AC; Christensen AF; Junker P; Lindegaard HM
Dan Med Bull; 2011 Apr; 58(4):A4257. PubMed ID: 21466765
[TBL] [Abstract][Full Text] [Related]
60. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA).
Hetland ML; Ejbjerg B; Hørslev-Petersen K; Jacobsen S; Vestergaard A; Jurik AG; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Skjødt H; Pedersen JK; Majgaard O; Svendsen AJ; Ellingsen T; Lindegaard H; Christensen AF; Vallø J; Torfing T; Narvestad E; Thomsen HS; Ostergaard M;
Ann Rheum Dis; 2009 Mar; 68(3):384-90. PubMed ID: 18388160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]